Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711706 | 0.85 | ACE2 (0.41) | ACE2ACECYP11B1CYP11B2MME | |
| SCHEMBL7381303 | 0.81 | ACE2 (0.44) | ACE2ACECYP11B1CYP11B2MME | |
| SCHEMBL3715236 | 0.81 | ACE2 (0.39) | ACE2ACECYP11B1CYP11B2GRN | |
| SCHEMBL3704209 | 0.79 | ACE2 (0.44) | ACE2ACECTSKCYP11B1CYP11B2 | |
| SCHEMBL1658524 | 0.79 | ACE2 (0.60) | ACE2ACECTSKCYP11B1CYP11B2 | |
| SCHEMBL8249276 | 0.79 | ACE2 (0.60) | ACE2ACECTSKCYP11B1CYP11B2 | |
| SCHEMBL7375023 | 0.79 | ACE2 (0.39) | ACE2ACECYP11B1CYP11B2MME | |
| SCHEMBL3709303 | 0.78 | ACE2 (0.52) | ACE2ACECYP11B1CYP11B2 | |
| SCHEMBL3710373 | 0.78 | ACE2 (0.43) | ACE2ACECYP11B1CYP11B2MME | |
| SCHEMBL3714339 | 0.78 | ACE2 (0.43) | ACE2ACECYP11B1CYP11B2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | claimed |
| WO-2009049022-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2009-04-16 | — | — | WO | claimed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |